(2E)-1-{[1,1'-biphenyl]-4-yl}-3-(3-nitrophenyl)prop-2-en-1-one, 95.0%, 2g

N-(2-Aminophenyl)-4-fluorobenzene-1-sulfonamide, 95%, 250mg

4-Cyanopiperidine, 98.0%, 10g

3-Bromo-2-methyl-6-(trifluoromethyl)pyridine, 95.0%, 1g

tert-butyl 3-(hexylamino)-2-methylpropanoate, 95.0%, 2g

Colonna capillare per GC ROTI®Cap-1, 25 m, 0,32 mm, 0,35 µm, 1 Pezzo(i)

2-(Methyl(4-nitrophenyl)amino)acetonitrile, 95+%, 5g

2,6-Dibromo-N-(2-nitrophenyl)aniline, 97%, 25g

2,2-Dimethyl-4-oxo-3,8,11,14,17,20-hexaoxa-5-azatricosan-23-oic acid, 97%, 5g

(2S)-2-[[[[3,5-Bis(trifluoromethyl)phenyl]amino]thioxomethyl]amino]-N-(diphenylmethyl)-N,3,3-trimethylbutanamide, 97%, 250mg

(R)-tert-Butyl 3-[(4-bromophenyl)methyl]aminopiperidine-1-carboxylate, 95.0%, 1g

N,N'-(pentane-1,5-diyl)bis(5-(dimethylamino)naphthalene-1-sulfonamide), 98%, 100mg

2-Chloro-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one, 98%, 50mg